Intellia Therapeutics
NTLA
293 hedge funds and large institutions have $1.16B invested in Intellia Therapeutics in 2024 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 127 increasing their positions, 68 reducing their positions, and 49 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 68
43% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $11.5M
31% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 49
5.69% more ownership
Funds ownership: 91.8% → 97.48% (+5.7%)
4% more funds holding
Funds holding: 283 → 293 (+10)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less capital invested
Capital invested by funds: $1.92B → $1.16B (-$757M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22.8M |
| 4 |
Morgan Stanley
New York
|
+$19.3M |
| 5 |
BlackRock
New York
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$102M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$42.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$30.1M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$28.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$17M |
NTLA Hedge Fund Activity: Q4 2024 in Review
293 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2024, worth a combined $1.16B — down 40% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new NTLA positions and 49 closed out — a net gain of 15 holders — while 127 added to existing stakes and 68 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $24.3M. The largest seller was Deep Track Capital, exiting entirely with an estimated $102M sold.
- 293 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2024, up from 283 in Q3 2024.
- Funds reported $1.16B of Intellia Therapeutics stock for Q4 2024, down 40% quarter-over-quarter.
- 64 funds opened new Intellia Therapeutics positions in Q4 2024 and 49 closed out, a net change of +15 holders.
- The largest Intellia Therapeutics buyer in Q4 2024 was Balyasny Asset Management, an estimated $24.3M added.
- The largest Intellia Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $102M sold.
Based on aggregated 13F filings for Q4 2024.